瑞舒伐他汀对冠心病合并阵发性房颤患者炎症因子及左房内径的影响

Effect of rosuvastatin on inflammation factor and left diameter in patients with coronary heart disease and atrial fibrillation

目的探讨瑞舒伐他汀对冠心病合并阵发性房颤患者炎症因子及其左房内径的影响。方法80例患者随机分配到对照组和观察组。对照组采用常规治疗，再给予胺碘酮治疗，观察组在此基础上应用瑞舒伐他汀治疗，观察两组治疗效果、CRP水平、左房内径。结果观察组总有效率为95．0％，对照组为85．0％，组间对比差异有统计学意义（P〈0．05）。两组治疗前后的CRP、观察组治疗前后LAD差异具有统计学意义（P〈0．05）；经治疗后，组间CRP和LAD差异具有统计学意义（P〈0．05）。结论瑞舒伐他汀能有效降低CRP水平，有效抑制左心房内径的扩大，减少房颤的发生。

Objective To investigate effect of rosuvastatin on inflammation factor and left diameter in patients with coronary heart disease and atrial fibrillation. Methods 80 patients were randomly assigned to control group and observation group. Control group was given conventional coronary treatment and amiodarone, observation group was given rosuvastatin on the basis of control group. CRP, left atrial diameter were observed to evaluate the therapeutic effect. Results The total effective rate in observation group was 95.0%, while that in control group was 85.0%, with significant difference between two groups （P 〈 0.05）. Before and after treatment, CRP in two groups had statistically significant differences （P 〈 0.05）. Before and after treatment, LAD in observation group had a statistically significant difference （P 〈 0.05）. After treatment, CRP and LAD between two groups had significant differences （P 〈 0.05）. Conclusion Rosuvastatin can effectively reduce CRP level, inhibit expansion of left atrial diameter and reduce the incidence of atrial fibrillation.